Evidence map›Paper›PMID 38279038›Full record

Observational studyEye (London, England)2024

Short-term response to anti-VEGF as indicator of visual prognosis in refractory age-related macular degeneration.

Anthony Gigon, Antonio Iskandar, Sophie Kasser, Sacha Naso, Marta Zola, Irmela Mantel

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Anthony GigonDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-5457-7871
Antonio IskandarDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland.
Sophie KasserDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland.
Sacha NasoDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland.
Marta ZolaDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1432-4201
Irmela MantelDepartment of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Foundation Asile des Aveugles, Lausanne, Switzerland. irmela.mantel@fa2.ch.ORCID http://orcid.org/0000-0002-8822-8194
Fondation Asile des Aveugles · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSome patients with neovascular age-related macular degeneration (nAMD) respond insufficiently to anti-VEGF treatment despite maximal monthly intravitreal injections. Their short-term response between injections was investigated for extent and visual prognosis. SUBJECTS/

methodsMonocentric retrospective observational study. 45 eyes from 41 patients with refractory nAMD (who previously received at least 12 months of anti-VEGF treatment), evaluated by optical coherence tomography (OCT) in between monthly anti-VEGF injections. The fluid profile on OCT was evaluated before, 1 week after, and 1 month after an intravitreal injection, using central retinal thickness (CRT), manual measurements, and fluid specific volumetric measurements performed by an automated algorithm based on artificial intelligence.

resultsA significant improvement was found at week 1 in terms of CRT (p < 0.0001), intraretinal (IRF) (p = 0.007), subretinal fluid (SRF) (p < 0.0001), and pigment epithelium detachment (PED) volume (p < 0.0001). Volumetric fluid measures revealed a >50% reduction at week 1 for both IRF and SRF for approximately two-thirds of eyes. Poorer short-term response was associated with larger exudative fluid amounts (IRF + SRF) (p = 0.003), larger PED (p = 0.007), lower visual acuity (p = 0.004) and less anatomic changes at treatment initiation (p < 0.0001). Univariate and multivariate analysis revealed that visual outcomes 4 and 5 years later was significantly worse with weaker short-term responsiveness (p = 0.005), with the presence of atrophy (p = 0.01) and larger PED volumes (p = 0.002).

conclusionsIncomplete responders to anti-VEGF showed a significant short-term response, identifiable at 1 week after injection, with rapid recurrence at 1 month. Weaker short-term responsiveness at 1 week was associated with poorer long term visual prognosis. These patients may need adjuvant treatment to improve their prognosis.

Indexed as

Angiogenesis InhibitorsIntravitreal InjectionsRanibizumabSubretinal FluidTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityWet Macular DegenerationAgedAged, 80 and overBevacizumabFemaleHumansMaleMiddle AgedPrognosisAngiogenesis InhibitorsBevacizumabRanibizumabReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID38279038
PMCPMC11076480
OpenAlexW4391251870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.